All public logs
Jump to navigation
Jump to search
Combined display of all available logs of wikidoc. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).
- 13:31, 22 February 2024 Mohammad Nikoohemmat talk contribs created page Birch triterpenes (Created page with "{{DrugProjectFormSinglePage |authorTag=Mohammad Nikoohemmat |genericName=birch triterpenes }}")
- 13:24, 22 February 2024 Mohammad Nikoohemmat talk contribs created page Eplontersen (Created page with "{{DrugProjectFormSinglePage |authorTag=Mohammad Nikoohemmat |genericName=Eplontersen |aOrAn=a |drugClass=transthyretin-directed antisense oligonucleotide |indicationType=treatment |indication=WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. |adverseReactions=Most common adverse reactions (that occurred in at least 9% of patients treated with WAINUA) were vitamin A decreased and vomiting. |fdaLIADAdult...")
- 12:33, 22 February 2024 Mohammad Nikoohemmat talk contribs created page Template:MNH (Created page with "Mohammad Nikoohemmat, M.D.[mailto:mohammadnikoo1375@gmail.com]")
- 16:38, 21 February 2024 Badgettrg talk contribs created page Template:Math2 (Created page with "<span class="texhtml {{#if:{{{big|}}}{{{size|}}}|texhtml-big}}" {{#if:{{{big|}}}{{{size|}}}|style="font-size:{{{size|165%}}};"}}>{{{1}}}</span><!-- -->{{#invoke:Check for unknown parameters|check | unknown = {{main other|_VALUE_}} | showblankpositional=1 | preview = unknown parameter "_VALUE_" (consider using <code>{{!}}1=</code>, <code><nowiki>{{!}}</nowiki></code>, <code><nowiki>{{=}}</nowiki></code>) | 1 | big | si...")
- 06:21, 21 February 2024 Alen Antony talk contribs created page Olutasidenib (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=Olutasidenib |aOrAn=a |drugClass=isocitrate dehydrogenase-1 (IDH1) inhibitor |indicationType=treatment |indication=relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. |hasBlackBoxWarning=Yes |adverseReactions=nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, mucositis, arthralgia, fatigue, pyrexia...")
- 14:13, 20 February 2024 Badgettrg talk contribs created page Treatment outcome (Created page with "{{SI}} {{RGB}} In Quality of Health Care, '''{{PAGENAME}}''' is defined as "Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series."<ref>{{MeSH}}</ref> ==Statistical methods== * The minimal clinically important differences (MCID) has been proposed as >0.5 standard deviation imp...")
- 15:11, 19 February 2024 Matt Pijoan talk contribs created page Template:Image (Created page with "<templatestyles src="Image/styles.css"/><div class="t-image {{#ifeq:{{{padding|}}}|no||t-image-padding}}" {{#if:{{{width|}}}|style="max-width:{{{width}}}%"}}> [[File:{{{file|File:MattP(1).png}}}|{{{imagewidth|400}}}px|{{#ifeq:{{{border|}}}|yes|border{{!}}}}alt={{{caption|}}}|{{#if:{{{link|}}}|link={{{link|}}}}}]]{{#if: {{{caption|}}}| <p class="t-image-caption"> {{{caption}}} </p>}} </div><noinclude> {{documentation|content= {{Uses TemplateStyles|Template:Image/styles.cs...")
- 16:17, 18 February 2024 Badgettrg talk contribs created page Back pain monitoring response to therapy (Created page with "__NOTOC__ {{Back pain}} {{CMG}} {{AE}} {{ZMalik}} ==Overview== The Oswestry low back pain disability questionnaire (ODQ) can measure the response to therapy.<ref name="pmid6450426">{{cite journal| author=Fairbank JC, Couper J, Davies JB, O'Brien JP| title=The Oswestry low back pain disability questionnaire. | journal=Physiotherapy | year= 1980 | volume= 66 | issue= 8 | pages= 271-3 | pmid=6450426 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi...")
- 03:15, 16 February 2024 Kosar Doraghi talk contribs created page Lasmiditan (Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=Lasmiditan (REYVOW) |aOrAn=a |drugClass=serotonin (5-HT) 1F receptor agonist |indicationType=treatment |indication=migraine with or without aura in adults |hasBlackBoxWarning=Yes |adverseReactions=dizziness, fatigue, paresthesia, and sedation |blackBoxWarningTitle=Warning |blackBoxWarningBody=Driving Impairment: *Central Nervous System (CNS) Depression: Do not use in combination...")
- 03:03, 16 February 2024 Kosar Doraghi talk contribs created page File:IMG 0837.jpeg
- 03:03, 16 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0837.jpeg
- 02:58, 16 February 2024 Kosar Doraghi talk contribs created page File:IMG 0839.jpeg
- 02:58, 16 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0839.jpeg
- 02:56, 16 February 2024 Kosar Doraghi talk contribs created page File:IMG 0838.jpeg
- 02:56, 16 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0838.jpeg
- 06:30, 15 February 2024 Alen Antony talk contribs created page Lenacapavir (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=lenacapavir }}")
- 02:00, 15 February 2024 Alara E. Dagsali talk contribs created page 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC) (Created page with "{{ADA guidelines}} {{CMG}} {{AE}} {{SCh}}; {{MehdiP}}; {{TarekNafee}} ==2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)<ref name="pmid37622663">{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines f...")
- 01:01, 15 February 2024 Kosar Doraghi talk contribs created page Ponesimod (Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=Ponesimod (PONVORY) |aOrAn=a |drugClass=sphingosine 1-phosphate receptor modulator |indicationType=treatment |indication=relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults |hasBlackBoxWarning=Yes |adverseReactions=upper respiratory tract infection, hepatic transaminase elevation, and ...")
- 00:56, 15 February 2024 Kosar Doraghi talk contribs created page File:IMG 0834.jpeg
- 00:56, 15 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0834.jpeg
- 00:55, 15 February 2024 Kosar Doraghi talk contribs created page File:IMG 0833.jpeg
- 00:55, 15 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0833.jpeg
- 00:49, 15 February 2024 Kosar Doraghi talk contribs created page File:IMG 0832.jpeg
- 00:49, 15 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0832.jpeg
- 00:48, 15 February 2024 Kosar Doraghi talk contribs created page File:IMG 0829.jpeg
- 00:48, 15 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0829.jpeg
- 00:46, 15 February 2024 Kosar Doraghi talk contribs created page File:IMG 0831.jpeg
- 00:46, 15 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0831.jpeg
- 21:25, 14 February 2024 Alen Antony talk contribs created page Tirzepatide (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=tirzepatide |aOrAn=a |drugClass=glucagon-like peptide-1 (GLP-1) receptor agonist |indicationType=treatment |indication=type 2 diabetes mellitus in adults in adjunct to diet and exercise. |hasBlackBoxWarning=Yes |adverseReactions=pancreatitis,hypoglycemia with concomitant use of insulin or insulin secretagogues, acute kidney injury, severe gastrointestinal disease, acute gallbladder disease, dia...")
- 18:30, 14 February 2024 Kosar Doraghi talk contribs created page Dasiglucagon (Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=Dasiglucagon (ZEGALOGUE) |aOrAn=an |drugClass=anti-hypoglycemic |indicationType=treatment |indication=severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and older |hasBlackBoxWarning=Yes |adverseReactions=nausea, vomiting, headache, diarrhea, and injection site pain |blackBoxWarningTitle=Allergic reactions |blackBoxWarningBody=increase in blood pressure in Patients wi...")
- 18:17, 14 February 2024 Kosar Doraghi talk contribs created page File:IMG 0828.jpeg
- 18:17, 14 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0828.jpeg
- 18:16, 14 February 2024 Kosar Doraghi talk contribs created page File:IMG 0827.jpeg
- 18:16, 14 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0827.jpeg
- 18:13, 14 February 2024 Kosar Doraghi talk contribs created page File:IMG 0822.jpeg
- 18:13, 14 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0822.jpeg
- 18:12, 14 February 2024 Kosar Doraghi talk contribs created page File:IMG 0826.jpeg
- 18:12, 14 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0826.jpeg
- 18:07, 14 February 2024 Kosar Doraghi talk contribs created page File:IMG 0824.jpeg
- 18:07, 14 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0824.jpeg
- 18:05, 14 February 2024 Kosar Doraghi talk contribs created page File:IMG 0823.jpeg
- 18:05, 14 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0823.jpeg
- 17:59, 14 February 2024 Kosar Doraghi talk contribs created page File:IMG 0820.jpeg
- 17:59, 14 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0820.jpeg
- 17:58, 14 February 2024 Kosar Doraghi talk contribs created page File:IMG 0819.jpeg
- 17:58, 14 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0819.jpeg
- 07:05, 14 February 2024 Alen Antony talk contribs created page Spesolimab-sbzo (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=Spesolimab-sbzo |drugClass=humanized monoclonal Immunoglobulin G1 antibody |indicationType=treatment |indication=generalized pustular psoriasis (GPP) flares in adults. |adverseReactions=infections, nausea, vomiting, headache, fatigue, Infusion site hematoma and bruising. |fdaLIADAdult=SPEVIGO is indicated for the treatment of generalized pustular psoriasis (GPP) flares in adults. SPEVIGO is administer...")
- 21:57, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0813.jpeg
- 21:57, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0813.jpeg
- 21:56, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0812.jpeg
- 21:56, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0812.jpeg
- 21:54, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0817.jpeg
- 21:54, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0817.jpeg
- 21:51, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0818.jpeg
- 21:51, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0818.jpeg
- 21:50, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0816.jpeg
- 21:50, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0816.jpeg
- 21:47, 13 February 2024 Kosar Doraghi talk contribs created page Vericiguat (Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=VERQUVO-vericiguat |aOrAn=a |drugClass=soluble guanylate cyclase (sGC) stimulator |indicationType=treatment |indication=heart failure with reduced ejection fraction (HFrEF), reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less t...")
- 21:43, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0815.jpeg
- 21:43, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0815.jpeg
- 03:20, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0810.jpeg
- 03:20, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0810.jpeg
- 03:18, 13 February 2024 Kosar Doraghi talk contribs created page Tapinarof (Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=VTAMA- tapinarof cream |aOrAn=an |drugClass=aryl hydrocarbon receptor agonist |indicationType=treatment |indication=plaque psoriasis in adults |adverseReactions=folliculitis, nasopharyngitis, contact dermatitis, headache, and pruritus |fdaLIADAdult=Cream, 1% Each gram of VTAMA cream contains 10 mg of tapinarof in a white to off-white cream. *Apply a thin layer of VTAMA cream to affected ar...")
- 03:14, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0809.jpeg
- 03:14, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0809.jpeg
- 03:12, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0808.jpeg
- 03:12, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0808.jpeg
- 03:10, 13 February 2024 Kosar Doraghi talk contribs created page File:IMG 0807.jpeg
- 03:10, 13 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0807.jpeg
- 22:30, 12 February 2024 Alen Antony talk contribs created page Mosunetuzumab-axgb (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=mosunetuzumab-axgb |aOrAn=a |drugClass=humanized monoclonal antibody |indicationType=treatment |indication=relapsing or refractory follicular lymphoma in adults after 2 or more lines of systemic therapy. |hasBlackBoxWarning=Yes |adverseReactions=cytokine release syndrome, fatigue, rash, pyrexia, and headache. |blackBoxWarningTitle=Cytokine Release Syndrome (CRS) |blackBoxWarningBody=Cytok...")
- 17:40, 12 February 2024 Kosar Doraghi talk contribs created page Spevigo- spesolimab-sbz (Created page with "{{DrugProjectFormSinglePage |authorTag={{KDRG}} |genericName=spesolimab-sbzo |aOrAn=an |drugClass=interleukin-36 receptor antagonis |indicationType=treatment |indication=generalized pustular psoriasis flares in adults |hasBlackBoxWarning=Yes |adverseReactions=asthenia and fatigue, nausea and vomiting, headache, pruritus and prurigo, infusion site hematoma and bruising, and urinary tract infection. |blackBoxWarningTitle=Warning: Hyp...")
- 22:23, 11 February 2024 Edzelco talk contribs created page Mavacamten (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=mavacamten |aOrAn=a |drugClass=cardiac myosin inhibitor |indicationType=treatment |indication=adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms |hasBlackBoxWarning=Yes |adverseReactions=dizziness (27%) and syncope (6%) |blackBoxWarningTitle=WARNING: RISK OF HEART...")
- 06:13, 11 February 2024 Alen Antony talk contribs created page Template:AAP (Created page with "Alen Antony Pathil, M.D.[mailto:alenantony657@gmail.com]")
- 19:04, 10 February 2024 Edzelco talk contribs created page Oteseconazole (Created page with "{{DrugProjectFormSinglePage |genericName=oteseconazole |aOrAn=an |drugClass=azole antifungal |indicationType=prevention |indication=recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential |adverseReactions=headache and nausea |fdaLIADAdult=VIVJOA Capsules: 150 mg of oteseconazole in lavender hard gelatin capsules imprinted with OTE 150 in black ink. Fluconazole is not supplied in the carton. |co...")
- 19:02, 10 February 2024 Edzelco talk contribs created page File:VIVJOA label3.png
- 19:02, 10 February 2024 Edzelco talk contribs uploaded File:VIVJOA label3.png
- 19:02, 10 February 2024 Edzelco talk contribs created page File:VIVJOA label2.png
- 19:02, 10 February 2024 Edzelco talk contribs uploaded File:VIVJOA label2.png
- 19:02, 10 February 2024 Edzelco talk contribs created page File:VIVJOA label.png
- 19:02, 10 February 2024 Edzelco talk contribs uploaded File:VIVJOA label.png
- 19:02, 10 February 2024 Edzelco talk contribs created page File:VIVJOA structure.png
- 19:02, 10 February 2024 Edzelco talk contribs uploaded File:VIVJOA structure.png
- 06:17, 10 February 2024 Kosar Doraghi talk contribs created page Ublituximab-xiiy (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=BRIUMVI™ (ublituximab-xiiy |aOrAn=a |drugClass=CD20-directed cytolytic antibody |indicationType=treatment |indication=relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults |hasBlackBoxWarning=Yes |adverseReactions=infusion reactions and upper respiratory...")
- 06:14, 10 February 2024 Kosar Doraghi talk contribs created page File:IMG 0806.jpeg
- 06:14, 10 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0806.jpeg
- 06:13, 10 February 2024 Kosar Doraghi talk contribs created page File:IMG 0805.jpeg
- 06:13, 10 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0805.jpeg
- 06:09, 10 February 2024 Kosar Doraghi talk contribs created page File:IMG 0799.jpeg
- 06:09, 10 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0799.jpeg
- 22:35, 7 February 2024 User account Alen Antony talk contribs was created by Alberto Castro Molina talk contribs
- 17:15, 7 February 2024 Kosar Doraghi talk contribs created page LYTGOBI- futibatinib (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=Futibatinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. This indication is approved under accelerated approval based on overall respons...")
- 05:03, 7 February 2024 Kosar Doraghi talk contribs created page File:IMG 0790.jpeg
- 05:03, 7 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0790.jpeg
- 05:01, 7 February 2024 Kosar Doraghi talk contribs created page File:IMG 0787.jpeg
- 05:01, 7 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0787.jpeg
- 04:56, 7 February 2024 Kosar Doraghi talk contribs created page File:IMG 0788.jpeg
- 04:56, 7 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0788.jpeg
- 00:47, 7 February 2024 Edzelco talk contribs created page Lutetium (177Lu) vipivotide tetraxetan (Created page with "{{DrugProjectFormSinglePage |genericName=lutetium (177Lu) vipivotide tetraxetan |aOrAn=a |drugClass=radioligand therapeutic agent |indicationType=treatment |indication=adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy |adverseReactions=fatigue, dry mout...")
- 00:44, 7 February 2024 Edzelco talk contribs created page File:Pluvicto label.png
- 00:44, 7 February 2024 Edzelco talk contribs uploaded File:Pluvicto label.png
- 00:44, 7 February 2024 Edzelco talk contribs created page File:Pluvicto structure.png
- 00:44, 7 February 2024 Edzelco talk contribs uploaded File:Pluvicto structure.png
- 22:17, 6 February 2024 Kosar Doraghi talk contribs created page File:IMG 0786.jpeg
- 22:17, 6 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0786.jpeg
- 22:07, 6 February 2024 Kosar Doraghi talk contribs created page File:IMG 0785.jpeg
- 22:07, 6 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0785.jpeg
- 22:05, 6 February 2024 Kosar Doraghi talk contribs created page File:IMG 0782.jpeg
- 22:05, 6 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0782.jpeg
- 21:45, 6 February 2024 Kosar Doraghi talk contribs created page File:IMG 0783.jpeg
- 21:45, 6 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0783.jpeg
- 21:44, 6 February 2024 Kosar Doraghi talk contribs created page File:IMG 0784.jpeg
- 21:44, 6 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0784.jpeg
- 21:18, 6 February 2024 Kosar Doraghi talk contribs created page Deucravacitinib (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=Deucravacitinib (SOTYKTU) |aOrAn=a |drugClass=tyrosine kinase 2 (TYK2) inhibitor |indicationType=treatment |indication=treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy |hasBlackBoxWarning=Yes |adverseReactions=hypersensitivity reaction, upper respiratory infections, blood creatine phosphokinase increased,...")
- 00:57, 6 February 2024 Edzelco talk contribs created page Nivolumab and relatlimab-rmbw (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=nivolumab and relatlimab-rmbw |aOrAn=a |drugClass=combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody |indicationType=treatment |indication=adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma |adverseReactions=immune-mediated pneumonitis, im...")
- 00:56, 6 February 2024 Edzelco talk contribs created page File:Nivolumab and relatlimab-rmbw label.png
- 00:56, 6 February 2024 Edzelco talk contribs uploaded File:Nivolumab and relatlimab-rmbw label.png
- 00:22, 6 February 2024 Edzelco talk contribs created page File:Ganaloxone bottle carton.png
- 00:22, 6 February 2024 Edzelco talk contribs uploaded File:Ganaloxone bottle carton.png
- 00:22, 6 February 2024 Edzelco talk contribs created page File:Ganaloxone bottle suspension label 50mg.png
- 00:22, 6 February 2024 Edzelco talk contribs uploaded File:Ganaloxone bottle suspension label 50mg.png
- 00:21, 6 February 2024 Edzelco talk contribs created page File:Ganaloxone structure.png
- 00:21, 6 February 2024 Edzelco talk contribs uploaded File:Ganaloxone structure.png
- 06:00, 5 February 2024 Kosar Doraghi talk contribs created page File:IMG 0781.jpeg
- 06:00, 5 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0781.jpeg
- 05:49, 5 February 2024 Kosar Doraghi talk contribs created page RELYVRIO (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=sodium phenylbutyrate/taurursodiol |aOrAn=a |drugClass=drug that containing the active ingredients sodium phenylbutyrate and taurursodiol |indicationType=treatment |indication=amyotrophic lateral sclerosis (ALS) in adults. |hasBlackBoxWarning=Yes |adverseReactions=diarrhea, abdominal discomfort , nausea, and upper respiratory tract infection |blackBo...")
- 05:05, 5 February 2024 Kosar Doraghi talk contribs created page File:IMG 0779.jpeg
- 05:05, 5 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0779.jpeg
- 05:04, 5 February 2024 Kosar Doraghi talk contribs created page File:IMG 0780.jpeg
- 05:04, 5 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0780.jpeg
- 23:11, 4 February 2024 Kosar Doraghi talk contribs created page File:IMG 0777-sodium phenylbutyrate.jpeg
- 23:11, 4 February 2024 Kosar Doraghi talk contribs uploaded File:IMG 0777-sodium phenylbutyrate.jpeg
- 20:56, 2 February 2024 Kosar Doraghi talk contribs created page File:Nexobrid-02.jpg
- 20:56, 2 February 2024 Kosar Doraghi talk contribs uploaded File:Nexobrid-02.jpg
- 20:44, 2 February 2024 Kosar Doraghi talk contribs created page File:Nexobrid-01.jpg
- 20:44, 2 February 2024 Kosar Doraghi talk contribs uploaded File:Nexobrid-01.jpg
- 15:47, 2 February 2024 Edzelco talk contribs created page Pacritinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Pacritinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L (1) |adverseReactions=diarrhea, thrombocytopenia, nausea, anemia, and peripheral edema |fdaLIADAdult=The recommended dosage of VONJO is 200 mg orally twi...")
- 15:47, 2 February 2024 Edzelco talk contribs created page File:Pacritinib Bottle Label.png
- 15:47, 2 February 2024 Edzelco talk contribs uploaded File:Pacritinib Bottle Label.png
- 15:47, 2 February 2024 Edzelco talk contribs created page File:Pacritinib Carton Label.png
- 15:47, 2 February 2024 Edzelco talk contribs uploaded File:Pacritinib Carton Label.png
- 15:47, 2 February 2024 Edzelco talk contribs created page File:Pacritinib supply.png
- 15:47, 2 February 2024 Edzelco talk contribs uploaded File:Pacritinib supply.png
- 15:47, 2 February 2024 Edzelco talk contribs created page File:Pacritinib structure.png
- 15:47, 2 February 2024 Edzelco talk contribs uploaded File:Pacritinib structure.png
- 03:51, 2 February 2024 Kosar Doraghi talk contribs created page NEXOBRID (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. |genericName=anacaulase-bcdb |aOrAn=a |indicationType=treatment |indication=eschar in adults with deep partial thickness or full thickness thermal burns. The safety and effectiveness of NEXOBRID have not been established for treatment of: Chemical or electrical burns, burns on the face, perineum, or genitalia, burns on the feet of patients with diabetes mellitus or on the feet of patients with occlusive vascular...")
- 16:13, 1 February 2024 Edzelco talk contribs created page Mitapivat (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=mitapivat |aOrAn=a |drugClass=pyruvate kinase activator |indicationType=treatment |indication=hemolytic anemia in adults with pyruvate kinase (PK) deficiency |adverseReactions=estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia |fdaLIADAdult=PYRUKYND is taken with or without food and swallowed whole. Do not split, crush, chew,...")
- 16:08, 1 February 2024 Edzelco talk contribs created page File:Mitapivat 5mg.png
- 16:08, 1 February 2024 Edzelco talk contribs uploaded File:Mitapivat 5mg.png
- 16:08, 1 February 2024 Edzelco talk contribs created page File:Mitapivat 5mg tablet blister pack.png
- 16:08, 1 February 2024 Edzelco talk contribs uploaded File:Mitapivat 5mg tablet blister pack.png
- 16:07, 1 February 2024 Edzelco talk contribs created page File:Mitapivat 20mg.png
- 16:07, 1 February 2024 Edzelco talk contribs uploaded File:Mitapivat 20mg.png
- 16:07, 1 February 2024 Edzelco talk contribs created page File:Mitapivat 20mg tablet blister pack.png
- 16:07, 1 February 2024 Edzelco talk contribs uploaded File:Mitapivat 20mg tablet blister pack.png
- 16:07, 1 February 2024 Edzelco talk contribs created page File:Mitapivat 50mg.png
- 16:07, 1 February 2024 Edzelco talk contribs uploaded File:Mitapivat 50mg.png
- 16:07, 1 February 2024 Edzelco talk contribs created page File:Mitapivat 50mg tablet blister pack.png
- 16:07, 1 February 2024 Edzelco talk contribs uploaded File:Mitapivat 50mg tablet blister pack.png
- 16:06, 1 February 2024 Edzelco talk contribs created page File:Mitapivat structure.png
- 16:06, 1 February 2024 Edzelco talk contribs uploaded File:Mitapivat structure.png
- 16:06, 1 February 2024 Edzelco talk contribs created page File:Mitapivat supply.png
- 16:06, 1 February 2024 Edzelco talk contribs uploaded File:Mitapivat supply.png
- 15:46, 1 February 2024 Edzelco talk contribs created page Sutimlimab-jome (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Sutimlimab-jome |aOrAn=a |drugClass=classical complement inhibitor |indicationType=treatment |indication=hemolysis in adults with cold agglutinin disease (CAD) |adverseReactions=in the CADENZA study (Part A) (incidence ≥18%) are rhinitis, headache, hypertension, acrocyanosis, and Raynaud's phenomenon. The most common adverse reactions in the CARDINAL study (incidence ≥...")
- 15:44, 1 February 2024 Edzelco talk contribs created page File:Sutimlimab-jome packaging.png
- 15:44, 1 February 2024 Edzelco talk contribs uploaded File:Sutimlimab-jome packaging.png
- 15:31, 1 February 2024 Edzelco talk contribs created page Faricimab-svoa (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Faricimab-svoa |aOrAn=a |drugClass=vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor |indicationType=treatment |indication=patients with neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO) |adverseReactions=cataract (15%) and [[conjunctival hemorrhage]...")
- 14:59, 1 February 2024 Edzelco talk contribs created page Tebentafusp-tebn (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Tebentafusp-tebn |aOrAn=a |drugClass=bispecific gp100 peptide-HLA-directed CD3 T cell engager |indicationType=treatment |indication=HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma |hasBlackBoxWarning=Yes |adverseReactions=cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache and vomiting. The most...")
- 01:46, 1 February 2024 Edzelco talk contribs created page File:Abrocitinib 200mg.png
- 01:46, 1 February 2024 Edzelco talk contribs uploaded File:Abrocitinib 200mg.png
- 01:46, 1 February 2024 Edzelco talk contribs created page File:Abrocitinib 100mg.png
- 01:46, 1 February 2024 Edzelco talk contribs uploaded File:Abrocitinib 100mg.png
- 01:43, 1 February 2024 Edzelco talk contribs created page File:Abrocitinib 50mg.png
- 01:43, 1 February 2024 Edzelco talk contribs uploaded File:Abrocitinib 50mg.png
- 01:39, 1 February 2024 Edzelco talk contribs created page File:Abrocitinib supply.png
- 01:39, 1 February 2024 Edzelco talk contribs uploaded File:Abrocitinib supply.png
- 01:32, 1 February 2024 Edzelco talk contribs created page File:Abrocitinib.png
- 01:32, 1 February 2024 Edzelco talk contribs uploaded File:Abrocitinib.png
- 01:31, 1 February 2024 Edzelco talk contribs created page Abrocitinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |indicationType=treatment |indication=adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. |blackBoxWarningTitle=WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOS...")
- 21:17, 31 January 2024 Edzelco talk contribs created page Daridorexant (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=daridorexant |aOrAn=an |drugClass=orexin receptor antagonist |indicationType=treatment |indication=adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance |adverseReactions=Common adverse reactions (reported in ≥ 5% of patients treated with QUVIVIQ and at an incidence ≥ than placebo) include headache and somnolence or fatigue...")
- 21:15, 31 January 2024 Edzelco talk contribs created page File:Clinical Studies 3.png
- 21:15, 31 January 2024 Edzelco talk contribs uploaded File:Clinical Studies 3.png
- 21:15, 31 January 2024 Edzelco talk contribs created page File:Clinical Studies 2.png
- 21:15, 31 January 2024 Edzelco talk contribs uploaded File:Clinical Studies 2.png
- 21:15, 31 January 2024 Edzelco talk contribs created page File:Clinical Studies 1.png
- 21:15, 31 January 2024 Edzelco talk contribs uploaded File:Clinical Studies 1.png
- 21:07, 31 January 2024 Edzelco talk contribs created page File:Effects of hepatic impairment and renal impairment on daridorexant PK.png
- 21:07, 31 January 2024 Edzelco talk contribs uploaded File:Effects of hepatic impairment and renal impairment on daridorexant PK.png
- 21:07, 31 January 2024 Edzelco talk contribs created page File:Effect of daridorexant on the PK of other compounds.png
- 21:07, 31 January 2024 Edzelco talk contribs uploaded File:Effect of daridorexant on the PK of other compounds.png
- 21:06, 31 January 2024 Edzelco talk contribs created page File:Effect of co-administered compounds on the PK of daridorexant.png
- 21:06, 31 January 2024 Edzelco talk contribs uploaded File:Effect of co-administered compounds on the PK of daridorexant.png
- 21:01, 31 January 2024 Edzelco talk contribs created page File:Packaging 3.png
- 21:01, 31 January 2024 Edzelco talk contribs uploaded File:Packaging 3.png
- 21:01, 31 January 2024 Edzelco talk contribs created page File:Packaging 2.png
- 21:01, 31 January 2024 Edzelco talk contribs uploaded File:Packaging 2.png
- 21:00, 31 January 2024 Edzelco talk contribs created page File:Packaging 1.png
- 21:00, 31 January 2024 Edzelco talk contribs uploaded File:Packaging 1.png
- 20:49, 31 January 2024 Edzelco talk contribs created page File:Daridorexant.png
- 20:49, 31 January 2024 Edzelco talk contribs uploaded File:Daridorexant.png
- 20:30, 31 January 2024 Alara E. Dagsali talk contribs created page Adagrasib (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E. Dagsali |genericName=adagrasib |aOrAn=an |indicationType=treatment |indication=KRAZATI is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test [see DOSAGE AND ADMINISTRATION (2.1)], who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on ob...")
- 19:36, 27 January 2024 Badgettrg talk contribs created page Hospital mortality (Created page with "{{SI}} '''{{PAGENAME}}''' is defined as "a vital statistic measuring or recording the rate of death from any cause in hospitalized populations."<ref>{{MeSH}}</ref> ==Predicting hospital mortality== Comparative cohort studies<ref name="pmid32427324">{{cite journal| author=Liu VX, Lu Y, Carey KA, Gilbert ER, Afshar M, Akel M | display-authors=etal| title=Comparison of Early Warning Scoring Systems for Hospitalized Patients With and Without Infection at Risk for In-H...")
- 16:04, 27 January 2024 Badgettrg talk contribs created page Mafld (#REDIRECT) Tag: New redirect
- 00:25, 25 January 2024 Edzelco talk contribs created page Orbifloxacin (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Orbifloxacin |aOrAn=a |drugClass=fluoroquinolone carboxylic acid derivatives |indicationType=treatment |indication=urinary tract infections (cystitis) in dogs caused by susceptible strains of <i>Staphylococcus pseudintermedius, Proteus mirabilis, Escherichia coli</i> and <i>Enterococcus faecalis</i>. |adverseReactions=In a field study, when the tablet formulation of orbifloxacin...")
- 00:16, 25 January 2024 Edzelco talk contribs created page File:Orbifloxacin packaging.png
- 00:16, 25 January 2024 Edzelco talk contribs uploaded File:Orbifloxacin packaging.png
- 00:15, 25 January 2024 Edzelco talk contribs created page File:Orbifloxacin suspension 2.png
- 00:15, 25 January 2024 Edzelco talk contribs uploaded File:Orbifloxacin suspension 2.png
- 00:15, 25 January 2024 Edzelco talk contribs created page File:Orbifloxacin suspension.png
- 00:15, 25 January 2024 Edzelco talk contribs uploaded File:Orbifloxacin suspension.png
- 00:15, 25 January 2024 Edzelco talk contribs created page File:Orbifloxacin structure.png
- 00:15, 25 January 2024 Edzelco talk contribs uploaded File:Orbifloxacin structure.png
- 14:28, 23 January 2024 Edzelco talk contribs created page Ado-Trastuzumab Emtansine (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Ado-trastuzumab emtansine |aOrAn=a |drugClass=HER2-targeted antibody and microtubule inhibitor conjugate |indicationType=treatment |indication=1.) patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: a.) Received prior therapy for metastatic disease, or b.) Developed disease recurrence during or wi...")
- 14:24, 23 January 2024 Edzelco talk contribs created page File:Ado-trastuzumab emtansine packaging 160mg.png
- 14:24, 23 January 2024 Edzelco talk contribs uploaded File:Ado-trastuzumab emtansine packaging 160mg.png
- 14:22, 23 January 2024 Edzelco talk contribs created page File:Ado-trastuzumab emtansine packaging.png
- 14:22, 23 January 2024 Edzelco talk contribs uploaded File:Ado-trastuzumab emtansine packaging.png
- 14:19, 23 January 2024 Edzelco talk contribs created page File:Ado-trastuzumab emtansine supply.png
- 14:19, 23 January 2024 Edzelco talk contribs uploaded File:Ado-trastuzumab emtansine supply.png
- 14:19, 23 January 2024 Edzelco talk contribs created page File:Ado-trastuzumab emtansine structure.png
- 14:19, 23 January 2024 Edzelco talk contribs uploaded File:Ado-trastuzumab emtansine structure.png
- 23:32, 22 January 2024 Edzelco talk contribs created page Omacetaxine mepesuccinate (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Omacetaxine mepesuccinate (SYNRIBO) |aOrAn=an |drugClass=injection |indicationType=treatment |indication=adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI) |fdaLIADAdult=*Induction Dose: 1.25 mg/m2 administered by subcutaneous injection twice daily for 14 consecutive days of a 28-day cycle. *Maint...")
- 23:08, 22 January 2024 Edzelco talk contribs created page Adipiodone (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Adipiodone meglumine |aOrAn=a |drugClass=a tri-iodinated benzoate derivative and an ionic dimeric contrast agent |indicationType=procedure |indication=diagnostic imaging, as this agent blocks x-ray and appears opaque on x-ray film; thereby it enhances the visibility of the bile ducts and gallbladder during cholangiography and cholecystography procedures |adverseReactions=epilepsy, abdominal pain, and tremor...")
- 21:17, 22 January 2024 Edzelco talk contribs created page File:Adipiodine FDA-Approved Drugs.png
- 21:17, 22 January 2024 Edzelco talk contribs uploaded File:Adipiodine FDA-Approved Drugs.png
- 21:12, 22 January 2024 Edzelco talk contribs created page File:Structure of Adipiodine.png
- 21:12, 22 January 2024 Edzelco talk contribs uploaded File:Structure of Adipiodine.png
- 16:42, 22 January 2024 Edzelco talk contribs created page File:Oclatinib.png
- 16:42, 22 January 2024 Edzelco talk contribs uploaded File:Oclatinib.png
- 16:37, 22 January 2024 Edzelco talk contribs created page Oclacitinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |aOrAn=an |drugClass=immunomodulator |indicationType=treatment |indication=pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age |blackBoxWarningBody=This product is not for human use. Keep this and all drugs out of reach of children. For use in dogs only. Wash hands immediately after handling the tablets. In case of accidental eye contact, flush immediately with...")
- 16:34, 22 January 2024 Edzelco talk contribs created page File:APOQUEL tablets 16 mg Tablet Bottle Label.png
- 16:34, 22 January 2024 Edzelco talk contribs uploaded File:APOQUEL tablets 16 mg Tablet Bottle Label.png
- 16:34, 22 January 2024 Edzelco talk contribs created page File:APOQUEL tablets 5.4 mg Tablet Bottle Label.png
- 16:34, 22 January 2024 Edzelco talk contribs uploaded File:APOQUEL tablets 5.4 mg Tablet Bottle Label.png
- 16:34, 22 January 2024 Edzelco talk contribs created page File:APOQUEL tablets 3.6 mg Tablet Bottle Label.png
- 16:34, 22 January 2024 Edzelco talk contribs uploaded File:APOQUEL tablets 3.6 mg Tablet Bottle Label.png
- 15:49, 22 January 2024 Edzelco talk contribs created page Absorbable gelatin sponge (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Gelatin Sponge, Absorbable |aOrAn=a |drugClass=sterile, gelatin-base surgical sponge |indicationType=treatment |indication=bleeding as an adjunct to hemostasis when conventional procedure is ineffective. |brandNames=*Gelfoam |lookAlike=*Gelaspon *SurgiFoam }}")
- 00:21, 22 January 2024 Edzelco talk contribs created page File:2-(4-CHLOROPHENOXY)ETHANOL.png
- 00:21, 22 January 2024 Edzelco talk contribs uploaded File:2-(4-CHLOROPHENOXY)ETHANOL.png
- 22:16, 21 January 2024 Edzelco talk contribs created page AbobotulinumtoxinA (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Dysport |indication=Dysport is FDA approved for the treatment of cervical dystonia in adults, improvement of moderate to severe frown lines on the glabellar zone (eyebrows) of adults aged 65 years old or younger for a short period of time, and spasticity in people aged 2 years or older. |adverseReactions=Common adverse reactions include difficulty in breathing, speak...")
- 21:28, 21 January 2024 Edzelco talk contribs created page 2-(4-chlorphenoxy)-ethanol (Created page with "{{DrugProjectFormSinglePage |authorTag={{CMG}}; {{EdzelCo}} }}")
- 21:07, 18 January 2024 Kosar Doraghi talk contribs created page Template:KDRG (Created page with "Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com]")
- 20:22, 18 January 2024 User account Kosar Doraghi talk contribs was created by Alberto Castro Molina talk contribs
- 03:32, 17 January 2024 Badgettrg talk contribs created page Major depressive disorder monitoring response to therapy (Created page with "__NOTOC__ {{Major depressive disorder}} {{RGB}} ==Overview== Various definitions have been proposed for a response (Reliable Change Index (RCI)) and a remission to treatment. * PHQ-9 score of ≤9 combined with improvement of 50% (the original definition)<ref name="pmid11556941">{{cite journal| author=Kroenke K, Spitzer RL, Williams JB| title=The PHQ-9: validity of a brief depression severity measure. | journal=J Gen Intern Med | year= 2001 | volume= 16 | issue= 9 | pag...")
- 06:33, 4 January 2024 Rafael Garcia talk contribs created page Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Created blank page)
- 23:02, 30 December 2023 Badgettrg talk contribs moved page Attention-deficit hyperactivity disorder rating scales to Attention-deficit hyperactivity disorder rating scales for diagnosis (better name)
- 16:51, 30 December 2023 Badgettrg talk contribs created page Attention-deficit hyperactivity disorder rating scales (Created page with "__NOTOC__ {{RGB}} {{ADHD}} ==Overview== Several rating scales exist. * (CAARS) Conners' Adult ADHD Rating Scales is copyrighted and only available through purchase. https://www.wpspublish.com/caars-conners-adult-adhd-rating-scales ==References== {{Reflist|2}} Category:Psychiatry")
- 17:07, 21 December 2023 User account Hafiza Amna Qadeer talk contribs was created by Alberto Castro Molina talk contribs
- 17:00, 21 December 2023 User account Mohammad Nikoohemmat talk contribs was created by Alberto Castro Molina talk contribs
- 14:31, 21 December 2023 Rafael Garcia talk contribs created page Diabetic papillopathy (Created page with "Diabetic papillopathy")
- 04:28, 13 December 2023 Alberto Castro Molina talk contribs created page Anacaulase-bcdb (Created page with "{{DrugProjectFormSinglePage}}")